http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#Head
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#assertion
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#provenance
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#pubinfo
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#assertion
http://purl.obolibrary.org/obo/DOID_1040
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1040
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00073
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
http://www.w3.org/2000/01/rdf-schema#label
rituxan rituximab is a cd2 directed cytolytic antibody indicated for the treatment of adult patients with non hodgkin s lymphoma nhl 1 1 relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracycline based chemotherapy regimens chronic lymphocytic leukemia cll 1 2 previously untreated and previously treated cd2 positive cll in combination with fludarabine and cyclophosphamide fc rheumatoid arthritis ra in combination with methotrexate in adult patients with moderately to severely active ra who have inadequate response to one or more tnf antagonist therapies 1 3 granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 1 4 moderate to severe pemphigus vulgaris pv in adult patients 1 5 rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracycline based chemotherapy regimens rituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd2 positive cll rituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapies rituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00073
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#provenance
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#pubinfo
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#sig
http://purl.org/nanopub/x/hasSignature
e5h9nS5dXnodro3nmFY8W+0hg01dn5L4qBJPG0aSB3NPWWNphNZfg6aFt2Iw4fUAHjw/baIxHaXEGhnrgETaZZzsnZ/BxNoltpb8EKmd8QpCaiwtMZy1M87RDOD2Ugk7Yj9cc1B24eIScIy4QvgPrDxMwm+ZtX18UsTJ1ejcZMU=
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
http://purl.org/dc/terms/created
2021-07-03T15:22:39.359+02:00
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAAdnvsr8scocXUBdgUhmdkY1PJBk44pmU6iO4L7Ql5v4
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs